Neha Patil (Editor)

Quest Diagnostics

Updated on
Edit
Like
Comment
Share on FacebookTweet on TwitterShare on LinkedInShare on Reddit
Type
  
Public

Founder
  
Paul Brown

Industry
  
Health care

Customer service
  
0124 460 8888

Quest Diagnostics wwwunderconsiderationcombrandnewarchivesquest

Traded as
  
NYSE: DGXS&P 500 Component

Founded
  
New York City, United States (1967)

Area served
  
United States, Brazil, Mexico, United Kingdom, India

CEO
  
Steve Rusckowski (1 May 2012–)

Stock price
  
DGX (NYSE) US$ 99.17 +0.11 (+0.11%)20 Mar, 4:01 PM GMT-4 - Disclaimer

Headquarters
  
Madison, New Jersey, United States

Subsidiaries
  
Quest Diagnostics Nichols Institute

Profiles

Facebook
LinkedIn
Twitter
YouTube

Quest diagnostics action from insight


Quest Diagnostics Incorporated is a Fortune 500 company providing clinical laboratory services with headquarters in Madison, New Jersey. Founded in 1967 as Metropolitan Pathology Laboratory, Inc., it became an independent corporation with the Quest name on December 31, 1996. In addition to the United States, Quest Diagnostics also runs operations in United Kingdom, Mexico, Brazil, Puerto Rico and a laboratory in India and also has collaborative agreements internationally with various hospitals and clinics. It is a member of the Fortune 500 and the S&P 500, with corporate headquarters located in Madison, New Jersey. The company has approximately 44,000 employees, generates more than $7 billion in revenue and offers access to diagnostic testing services for cancer, cardiovascular disease, infectious disease and neurological disorders.

Contents

Quest diagnostics partnerships safeway


History

  • 1967: Founded by Paul A. Brown, MD as Metropolitan Pathology Laboratory, Inc., in New York.
  • 1969: Name Changed to MetPath, Inc., in Teaneck, New Jersey.
  • 1982: MetPath was acquired by what was then known as Corning Glass Works, and subsequently renamed Corning Clinical Laboratories.
  • 1996: Quest Diagnostics becomes an independent company as a spin-off from Corning. Kenneth Freeman appointed CEO.
  • 1997: Acquires clinical laboratory division of Branford, CT-based Diagnostic Medical Laboratory, Inc. (DML).
  • 1999: Acquires SmithKline Beecham Clinical Laboratories; GlaxoSmithKline still holds a large portion of Quest Diagnostics stock. The SmithKline Beecham acquisition includes a joint venture ownership with CompuNet Clinical Laboratory
  • 2000: Launch of Six Sigma program
  • 2001: Completes acquisition of Ohio-based MedPlus, Inc. (NASDAQ: MEDP), a healthcare technology company.
  • 2002: Completes acquisition of Virginia-based American Medical Laboratories, Inc. (AML) and an affiliated company of AML, LabPortal, Inc., for approximately $500 million in cash.
  • 2003: Completes acquisition of California-based Unilab Corporation (NASDAQ: ULAB) in a transaction valued at approximately $800 million.
  • 2005: Completes acquisition of Kansas-based LabOne, Inc. (NASDAQ: LABS) for approximately $934 million.
  • 2005: forms a strategic alliance with Ciphergen Biosystems to commercialize novel proteomic tests.
  • 2006: Completes acquisition of Virginia-based Focus Diagnostics, Inc., an infectious and immunologic disease laboratory, for approximately $185 million in cash.
  • 2007: Completes acquisition of Sweden-based Hemocue, a point-of-care diagnostic testing company.
  • 2007: Acquires AmeriPath (and subsidiary Specialty Laboratories) from Welsh, Carson, Anderson & Stowe, becoming the leading provider of cancer diagnostic testing services.
  • 2011: Acquires Athena Diagnostics from Thermo Fisher Scientific
  • 2011: Completes acquisition of Celera Corporation, a company that became famous by its sequencing of the Human Genome.
  • 2012: Names former Philips Healthcare CEO Stephen Rusckowski as CEO.
  • 2012: CEO, Surya Mohapatra, PhD (CEO From May 2004-April 2012) resigns after leading the company for 8 years
  • 2012: Quest Diagnostics bought all the labs including the business from UMASS Memorial Hospitals in Worcester, MA.
  • 2014: Acquires Solstas Lab Partners Group (and subsidiaries)
  • 2014: Acquires Summit Health, Inc.

    • Controversies

    Quest Diagnostics set a record in April 2009 when it paid $302 million to the government to settle a Medicare fraud case alleging the company sold faulty medical testing kits. It was the largest qui tam (whistleblower) settlement paid by a medical lab for manufacturing and distributing a faulty product. In May 2011, Quest paid $241 million to the state of California to settle a False Claims Act case that alleged the company had overcharged Medi-Cal, the state’s Medicaid program, and provided illegal kickbacks as incentives for healthcare providers to use Quest labs.

    References

    Quest Diagnostics Wikipedia
    (Text) CC BY-SA


    Similar Topics